Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I can't say that I'm mad the pictures have vanished. It just allows for us to get more cheap shares without the company's results being exposed. I believe the Fed probably had something to do with it. Can you imagine what this will do to the pharm and medical industry. Patients applying cannabis cream instead of receiving radiation. BIG $MONEY$ I really hope this works out. Hoping to get back into this play soon. Good luck all.
Any updates on the trial patients. I wanna know what the dude with the baseball sized tumor on his head looks like now. Did they have to stop posting pics of the trials because of the feds?
Where is Matty Simon? Anyone know? What's up newmedman. I can't keep my eyes of CBIS. Sold out awhile ago when she peaked and been prayin for .01's to get back in. Bought my shares a few months after the divy requirement so I was holding the boat for awhile.
Looks like dilution here. I was invested and glad I got out. Where's the divy? Looks like a lot of false promises here. I'm staying away from this one till election time.
Where's the 8K too? I don't blame them for not filing until they take their salaries. It's really sad to see because I feel this company has a lot of potential but it has too many hoops to jump through.
Good luck tho. I was a bag holder last year. I'll get back in when it drops to the 1-2 cent range.
Bones Jones?
I cannot believe this did not break .20 with biopsy news. I wonder what they will deliver this time. 5 more days to file, I can't imagine the books look too good.
I'm not spending another dime on this until I see financials and some revenue.
I was particularly bothered by the quality of the patient updates. They need to hire a higher quality PR creator. And please use spell check.
Were they using a polaroid camera?
Lostcoast you still buying bra? Or sittin on the sidelines?
More Fluff! More Red Coming IMO.
Hate to say it but I'm betting on some more RED! Don't get me wrong I love CBIS but IMO it'll drop down some.
What will happen with they drop the DIVY and increase the O/S to 850,000,000 shares. Thats nearly three times as much as what is trading now.
Is it just me or are they taking these pictures with a crappy camera and who is posting these updates. I think a middle schooler could do a better job.
I must admit that the tumors do look much better. RED with NEWS. Same ole story here. I think we will see a pattern of selling before the next pop. Last months run looking to be setting up similar to the next leg up.
What is the share price going to be once the divy comes out and the O/S is increased to 850,000,000? Any opinions out there?
I may hold out until divy comes and buy Class A shares.
This stock was up 2400% at .24 since 2011. That's a un realistic return when CBIS has not had any revenues to record on the books as of today and over 64 million in debt. I wonder how long it will take this company to get in the black. Probably pretty fast once their cancer treatments come out. Thier debt is tax deductible but Dr. Bobs 4 million annual salary requires a lot of cream and lip balm sales. Wonder what the profit margin is on them.
I like the direction the company is going in but IMO it's going to be a long time before it's truely valued $1.00. That would be a 10,000% gain on an investment made just over 3 months ago.
Shorts are going to keep murdering this most investors here are a goldfish in a sharks pool. This was clearly a pump and dump and it's unfortunate because I believe CBIS deserves more credit then they receive.
We will have to see what they say next. This will make an early morning run followed by all the scared people selling by the end of the day. IMO
Could be a flippers paradise in the morning.
If I'm correct weren't you bashing this stock a couple of weeks ago now your hoping for a miracle. How's it feel to be a short. Time for you to pay ur dues!
I have a feeling the chart is going to follow the same characteristics of the last run. Quick run followed by a couple of weeks of consolidation down to .06-08 range followed by another pop!
Maybe late March?
I'd like to think it will follow the same pattern. A pop in mid to late March from Biopsy Results.
But what do I know. I'm just a country boy from upstate NY.
Your absolutely right medman. I still believe. I will buy more when the time is right. I do hope you took some profits. If not it's just a matter of time before this company shows it's true strength. The pictures are clear evidence that CBIS is on to something. It will take some time but in the end you and the longs will be the winners. I sold everything I had because I'm not getting a divy.
They have a lot of competition in that market. It's going to be tough to penetrate it and capture market share. The cancer treating formula is where the money is.
Time will tell.
Wow, looks like they are trying to attack the OTC market first. Not a bad idea however I don't believe this is the news most people were looking for. I was looking for Cancer Curing Products. Sorry to say it guys but Gomez was right. This may dip back down into the .05-.08 levels.
Good luck to all. I think I'm gonna wait it out. Almost bought more at .135. Glad I held out and had to go to work today. Another dip down/sell off tomorrow IMO. Might set up for a nice run on Monday if it dips low enough.
Who is selling all of these shares?
MM's
Somebody made some serious profits today and most people are holding the bag.
Wow a lotta people holding the bag right now. This is healthy consolidation. CBIS needs to steady out before it makes it's next run.
Most longs were expecting this and are probably happy to see it. Where is the bottom? I'm guessing .12
Exactly what I thought last year when I bought at .09 then over the next year it bottomed out to .0085. However it is a year later and I feel there are more favorable variables. I hope your right tho and good luck to you. Tomorrow could be a flippers paradise IMO.
Just throwing it out there. This is from last year's Financials
Net Income per Employee -4,076,840
Not really sure but that seems to be a pretty high salary for a start up that has not shown any profit.
I guess now that I'm looking to re-invest I'm trying to determine if it's safe now or safer later.
So what's going to happen to the price of the stock when the divy hits.
From DEF 14C
Upon effectiveness of the Amendment, we will be authorized to issue 850,000,000 shares of Class B common stock (our current class) and 100,000,000 shares of
Class A common stock (our new class) and 1,000,000 shares of preferred stock.
There are only 250,000,000 of Class B shares now with a possible 50,000,000 more being added to pay for our new employees.
It definately makes me wonder.
Not saying it's not possible for this to go thru the ceiling. I may just hold my profits and buy some Class A shares when they come out and get a divy.
That way I'll always have the option to convert them to class B at a 30.1 ratio.
Thanks bud! You always have a way of making me feel better about my decesion. I think CBIS has struck gold!
Hey longs, I'm going to turn into a basher now so I can get back in. hahaha J/K Great day for you all and good luck. I don't know if I can watch anymore as it makes me sick I sold. Looking to get back in at the right opportunity if it presents itself.
Unbelieveable day. Cannot believe I gave away my shares. So depressed. Good Luck All
Hey Longs (matty, dayadoger, newmedman)! I'm feeling sick to my stomach right now. Just unloaded 2/3rds of my position of shares at close.
Still holding on to some freebies. Just want to thank you guys for keeping your positive outlook on this. Been here through the ups and downs with you and it's good to see CBIS so strong. Had to take some profits and keep some free shares as I wasn't here before Dec 31 2010. No divy in store for me. I'm gonna hold on to what I have left.
Thanks again for all of your positive insight.
CBIS LONG AND STRONG
Better slap that ask if you want in before the Product Launch and Biopsy results!
THIRD PARTY NEWS ON CBIS
http://finance.yahoo.com/news/Cancer-Drug-Market-Evolves-iw-3995947486.html?x=0
..
Cancer Drug Market Evolves - Cannabis Science and ARIAD Pharmaceuticals Poised to Benefit
The Paragon Report Provides Equity Research on Cannabis Science & ARIAD Pharmaceuticals
Press Release: Paragon Financial Limited – 2 hours 36 minutes ago.. .
.
..
.
.
Companies:.
.
.Ariad Pharmaceuticals Inc.
Cannabis Science, Inc.
.
.
.
RELATED QUOTES.
.
Symbol
Price
Change
ARIA
15.20
+0.14
.
.
..
.
.
NEW YORK, NY--(Marketwire -02/27/12)- Advances in cancer screening and treatment has caused the death rate from cancer to drop dramatically in recent years. Cancer death rates dropped by 1.8 percent per year in men and 1.6 percent per year in women between 2004 and 2008, according to the American Cancer Society's annual report on cancer statistics. The Paragon Report examines investing opportunities in the Healthcare sector and provides equity research on Cannabis Science Inc. (OTC.BB: CBIS.OB - News) & ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA - News). Access to the full company reports can be found at:
www.paragonreport.com/CBIS
www.paragonreport.com/ARIA
Death rates fell in all four of the most common cancers, lung, colon, breast and prostate, with lung cancer accounting for nearly 40 percent of the total drop in men and breast cancer account for 34 percent of the total decline in women, the American Cancer Society report finds.
The U.S. FDA has been approving cancer drugs at a faster rate than its European counterpart (the EMA), Friends of Cancer Research reports. Between 2003 and 2010, the FDA not only approved more new cancer drugs than did the EMA, it approved these drugs more quickly: of 23 drugs approved by both agencies, the median time from marketing submission to FDA approval was 182 days vs. EMA approval of 350 days according to the report.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Healthcare sector register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
ARIAD Pharmaceuticals' product pipeline includes Ponatinib, a pan BCR-ABL inhibitor in phase 2 clinical trial for applications in various hematological cancers and solid tumors; and AP26113, an anaplastic lymphoma kinase (ALK) inhibitor in preclinical studies for the treatment of various cancers, including non-small cell lung cancer, lymphoma, and neuroblastoma.
Cannabis Science, Inc., a development stage company, engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products. Earlier this month the company introduced a fourth cancer patient with basal cell carcinoma (skin cancer) on his left nostril, who is self-administering a topical cannabis extract and having noticeable results.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
..
THIRD PARTY NEWS ON CBIS
http://finance.yahoo.com/news/Cancer-Drug-Market-Evolves-iw-3995947486.html?x=0
..
Cancer Drug Market Evolves - Cannabis Science and ARIAD Pharmaceuticals Poised to Benefit
The Paragon Report Provides Equity Research on Cannabis Science & ARIAD Pharmaceuticals
Press Release: Paragon Financial Limited – 2 hours 36 minutes ago.. .
.
..
.
.
Companies:.
.
.Ariad Pharmaceuticals Inc.
Cannabis Science, Inc.
.
.
.
RELATED QUOTES.
.
Symbol
Price
Change
ARIA
15.20
+0.14
.
.
..
.
.
NEW YORK, NY--(Marketwire -02/27/12)- Advances in cancer screening and treatment has caused the death rate from cancer to drop dramatically in recent years. Cancer death rates dropped by 1.8 percent per year in men and 1.6 percent per year in women between 2004 and 2008, according to the American Cancer Society's annual report on cancer statistics. The Paragon Report examines investing opportunities in the Healthcare sector and provides equity research on Cannabis Science Inc. (OTC.BB: CBIS.OB - News) & ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA - News). Access to the full company reports can be found at:
www.paragonreport.com/CBIS
www.paragonreport.com/ARIA
Death rates fell in all four of the most common cancers, lung, colon, breast and prostate, with lung cancer accounting for nearly 40 percent of the total drop in men and breast cancer account for 34 percent of the total decline in women, the American Cancer Society report finds.
The U.S. FDA has been approving cancer drugs at a faster rate than its European counterpart (the EMA), Friends of Cancer Research reports. Between 2003 and 2010, the FDA not only approved more new cancer drugs than did the EMA, it approved these drugs more quickly: of 23 drugs approved by both agencies, the median time from marketing submission to FDA approval was 182 days vs. EMA approval of 350 days according to the report.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Healthcare sector register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
ARIAD Pharmaceuticals' product pipeline includes Ponatinib, a pan BCR-ABL inhibitor in phase 2 clinical trial for applications in various hematological cancers and solid tumors; and AP26113, an anaplastic lymphoma kinase (ALK) inhibitor in preclinical studies for the treatment of various cancers, including non-small cell lung cancer, lymphoma, and neuroblastoma.
Cannabis Science, Inc., a development stage company, engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products. Earlier this month the company introduced a fourth cancer patient with basal cell carcinoma (skin cancer) on his left nostril, who is self-administering a topical cannabis extract and having noticeable results.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
..
All aboard train's about to leave. Cannot wait for the exciting deveopments in store for the near future. Kane mentioned possible Biopsy results for March. If they are already preparing 4 products it's possible that CBIS has an ace up its sleeve.
So happy to be here and supporting the cause. Long and Strong.
Hopefully higher tho!
Setting up for a EOD rally IMO. I'm guessing a close at .0918
Setting up for a EOD rally IMO. I'm guessing a close at .0918
FAT CATS trying to get in as cheap as possible before another explosion next week.
MM's trying to bring it down and shake the tree. Not happening. CBIS has got it's roots dug in now.
who is the idiot selling shares right now?
CBIS knows what they are doing. GREAT NEWS!!!!!